More patients receive recommended heart failure treatment
An increasing proportion of patients with heart failure receive a combination of four medications shown to improve prognosis and recommended in guidelines. However, there is still room for improving adherence and persistence to heart failure therapy, which appears linked to a lower risk of hospitalisation for heart failure and cardiovascular death. These findings are shown by a new study from Karolinska Institutet published in the European Heart Journal.
The study includes 35,215 individuals with heart failure with reduced ejection fraction (HFrEF) registered in the national quality registry for heart failure, the Swedish Heart Failure Registry (SwedeHF), between 2016 and 2023. The four drug classes beta-blockers, ACE inhibitors/ARBs or ARNI, MRA, and SGLT2 inhibitors have been shown to improve prognosis and are recommended for all patients with HFrEF. The researchers examined how many receive all four recommended drug classes and how well patients adhere to treatment, based on dispensed prescriptions.
The results show that the use of all four drug classes increased over the period. In 2023, 93 per cent used beta-blockers, 95 per cent ACE inhibitors/ARBs or ARNI, 73 per cent MRA, and 83 per cent SGLT2 inhibitors. Six out of ten patients used all four medications.
"We see a clear improvement over time. At the same time, there is still room to increase the use of MRA in particular, which is the least used treatment", says senior author Gianluigi Savarese, Head of the Center for Heart Failure and Arrhythmia at the Department of Clinical Science and Education, Södersjukhuset
High adherence linked to better prognosis
For the combination of all four treatments, good adherence was observed in 85 per cent. The proportion who continued their medication after one year ranged between 77 per cent and 90 per cent for the individual treatments.
Good adherence to the drug classes was linked to a lower risk of hospitalisation due to heart failure or cardiovascular death.
SwedeHF, which is made possible by healthcare staff across the country, has contributed to many insights into how heart failure treatment is used in Sweden.
"Ten years ago, studies from SwedeHF showed that the use of heart failure treatment was limited and not increasing. It is therefore important that we can now show that improved use and adherence are achievable in routine clinical care, although there is still room to improve both prescription and adherence", says first author Felix Lindberg, postdoctoral researcher at the Department of Clinical Science and Education, Södersjukhuset
See the study for details of funding sources and any conflicts of interest.
Publication
Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription Lindberg F, Uijl A, Benson L, Valente V, Coats AJS, Böhm M, Metra M, Masi S, Lund LH, Rosano GMC, Savarese G. European Heart Journal, 2026; doi:10.1093/eurheartj/ehag199